LRP1B and lung adenocarcinoma: This research provides evidence that co-mutation of FAT3 and LRP1B may be a very promising novel biomarker for screening candidates of ICIs therapy in lung adenocarcinoma and lays a preliminary foundation for subsequent further exploration.